leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - Činidlá modifikujúce lipidy - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
atorvastatín/ezetimib teva 20 mg/10 mg
teva b.v., holandsko - atorvastatín a ezetimib - 31 - hypolipidaemica
atorvastatín/ezetimib teva 10 mg/10 mg
teva b.v., holandsko - atorvastatín a ezetimib - 31 - hypolipidaemica
atorvastatín/ezetimib teva 80 mg/10 mg
teva b.v., holandsko - atorvastatín a ezetimib - 31 - hypolipidaemica
atorvastatín/ezetimib teva 40 mg/10 mg
teva b.v., holandsko - atorvastatín a ezetimib - 31 - hypolipidaemica
atorvastatin teva pharma 10 mg
teva pharmaceuticals slovakia s.r.o., slovensko - atorvastatín - 31 - hypolipidaemica
atorvastatin teva pharma 20 mg
teva pharmaceuticals slovakia s.r.o., slovensko - atorvastatín - 31 - hypolipidaemica
atorvastatin teva pharma 40 mg
teva pharmaceuticals slovakia s.r.o., slovensko - atorvastatín - 31 - hypolipidaemica
atorvastatin teva pharma 80 mg
teva pharmaceuticals slovakia s.r.o., slovensko - atorvastatín - 31 - hypolipidaemica
atorvastatin stada 80 mg filmom obalené tablety
stada arzneimittel ag, nemecko - atorvastatín - 31 - hypolipidaemica